For example, repurposing of therapies targeting excitation–contraction coupling and Ca2+ homeostasis can be envisaged for CACNA1S or the SOCE pathway [70], or anti-oxidant modulators for PYROXD1-related myopathy. This evidence concerns the gene CACNA1S and myopathy.